
JUPITER NEUROSCIENCES, INC.
84
Recent developments highlight clinical progress, financing activities, and Nasdaq compliance challenges.
- Jupiter Neurosciences started a Phase 2a clinical trial of JOTROL for Parkinson's disease in October 2026 [N1].
- The company reported a wider loss in Q2 2026 and announced pricing of a $2 million direct offering in August 2026 [N2].
- Jupiter Neurosciences secured a $100 million term sheet for U.S. licensing rights to ALA-002 in May 2026 [N3].
- The company expanded the addressable market for its Nugevia™ supplement line focusing on GLP-1 users in January 2026 [N4].
- Jupiter Neurosciences showcased its lead program JOTROL at the DealFlow Discovery Conference in January 2026 [N5].
- The company highlighted the breakthrough JOTROL™ resveratrol platform with enhanced bioavailability and therapeutic potential in July 2025 [N6].
- Jupiter Neurosciences launched the Nugevia™ PWR cellular energy supplement for longevity in June 2025 [N7].
- Annika Sörenstam was appointed as the first brand ambassador for the Nugevia™ longevity supplement line in June 2025 [N8].
Jupiter Neurosciences, Inc. operates as a clinical-stage biotechnology company developing therapeutics targeting neurological and neurodegenerative diseases. Its lead program, JOTROL™, is a resveratrol-based platform designed to enhance bioavailability and therapeutic potential, currently in Phase 2a clinical trials for Parkinson's disease. The company also holds a license agreement with PharmAla for ALA-002, a Schedule I controlled substance, which involves significant development and commercialization obligations and regulatory compliance requirements. Jupiter Neurosciences has expanded its product portfolio with the Nugevia™ line of cellular energy supplements aimed at longevity. The company has faced financial challenges, including recurring losses and liquidity constraints, and has taken steps such as a reverse stock split to maintain Nasdaq listing compliance. Its operations depend on securing additional financing and meeting development milestones under licensing agreements.
Jupiter Neurosciences, Inc. is a clinical-stage biotech company focused on neurological therapeutics, notably developing JOTROL™ for Parkinson's disease and holding a license for ALA-002, a controlled substance requiring DEA compliance. The company has initiated a Phase 2a trial for JOTROL and secured a $100 million term sheet for ALA-002's U.S. licensing rights. Financially, as of September 30, 2026, the company reported a net loss of $7.22 million and faces liquidity challenges with a current ratio of 0.49. Management has expressed substantial doubt about the company's ability to continue as a going concern. The company has faced Nasdaq delisting risks due to market value deficiencies but completed a reverse stock split to regain compliance with minimum bid price requirements. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
The company has advanced its lead program JOTROL™ into Phase 2a clinical trials for Parkinson's disease, demonstrating progress in clinical development. Securing a $100 million term sheet for ALA-002's U.S. licensing rights indicates potential value in its licensed assets. Expansion of the Nugevia™ supplement line and strategic partnerships enhance its product portfolio and market reach. The reverse stock split and Nasdaq compliance efforts reflect management's commitment to maintaining market presence.
Jupiter Neurosciences faces significant financial challenges, including recurring losses, negative cash flows, and liquidity constraints with a current ratio below 1. The company has substantial obligations under its PharmAla license agreement, including milestone payments and regulatory compliance risks related to controlled substances. Nasdaq delisting risks due to failure to meet market value requirements pose threats to liquidity and capital raising ability. Failure to secure additional financing or meet development milestones could lead to operational curtailment or insolvency.
Jupiter Neurosciences' moat is primarily based on its proprietary JOTROL™ resveratrol platform with enhanced bioavailability and its licensing rights to ALA-002, a controlled substance with regulatory barriers to entry. The company's partnerships and licensing agreements, including the $100 million term sheet for ALA-002's U.S. rights, provide potential competitive advantages. However, as a clinical-stage company without commercial products, its moat is contingent on successful clinical development, regulatory approvals, and the ability to maintain financing and Nasdaq listing compliance.
• Liquidity and Going Concern Risk: The company has limited cash resources and a current ratio of 0.49 as of September 30, 2026, with management expressing substantial doubt about its ability to continue as a going concern without additional financing.
• Nasdaq Listing Compliance Risk: Jupiter Neurosciences has received Nasdaq delisting notices due to failure to meet minimum market value of listed securities requirements and is subject to potential delisting if compliance is not regained.
• License Agreement Obligations and Risks: The license agreement with PharmAla requires significant development and commercialization milestones payments and compliance with controlled substance regulations. Failure to meet obligations could result in termination and loss of rights to ALA-002.
• Regulatory and Market Acceptance Risks: ALA-002 is a Schedule I controlled substance requiring DEA rescheduling before marketing in the U.S., which may not occur timely or at all. Controlled substances may face public controversy affecting clinical enrollment, regulatory review, and market acceptance.
Business trends: Advancement of JOTROL clinical trials and expansion of supplement product lines alongside licensing deals for ALA-002.
Execution milestones: Completion of Phase 2a trial initiation, securing financing through direct offerings, and managing Nasdaq compliance including reverse stock split.
Key risks: Liquidity constraints, potential Nasdaq delisting, regulatory challenges with controlled substance licensing, and milestone payment obligations under license agreements.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Jupiter Neurosciences, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for neurological and neurodegenerative diseases.
- The company is developing JOTROL™, a resveratrol-based platform with enhanced bioavailability and therapeutic potential, targeting Parkinson's disease and other indications.
- Jupiter Neurosciences has initiated a Phase 2a clinical trial of JOTROL in Parkinson's disease as of October 2026.
- The company has a license agreement with PharmAla for ALA-002, a Schedule I controlled substance, which requires DEA registration and compliance with controlled substance laws.
- Jupiter Neurosciences secured a $100 million term sheet for U.S. licensing rights to ALA-002.
- The company launched Nugevia™, a science-driven cellular energy supplement line for longevity, and appointed Annika Sörenstam as its first brand ambassador.
- Jupiter Neurosciences completed a 1-for-75 reverse stock split in August 2026 to increase its stock price and regain Nasdaq compliance with minimum bid price requirements.
- The company has faced Nasdaq delisting notices due to failure to meet minimum market value of listed securities (MVLS) requirements and has appealed for extensions.
- As of September 30, 2026, the company had current assets of approximately $1.26 million and current liabilities of approximately $2.59 million, resulting in a current ratio of 0.49, indicating liquidity challenges.
- The company reported a net loss of approximately $7.22 million for the nine months ended September 30, 2026, with basic and diluted EPS of -7.42 USD per share.
- Management has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows, with cash on hand insufficient to fund operations for the next twelve months.
- The company has announced multiple financing efforts, including a $2 million direct offering priced in August 2026.
- The license agreement with PharmAla imposes significant development and payment obligations, including milestone payments up to $23.3 million for development and $73.3 million for commercialization, plus royalties on net sales.
- Failure to meet development deadlines under the PharmAla license could result in termination and loss of rights to ALA-002.
- The company’s common stock is listed on Nasdaq under ticker symbol JUNS.
- The company’s financial figures and liquidity ratios are summarized from the latest SEC filings and are provided for informational purposes only.
Generated 2026-11-17
- S1 | 2026-04-01 | 10-K
- S2 | 2026-11-16 | 10-Q
- N1 | 2026-10-06 | www.nasdaq.com | Jupiter Neurosciences Starts Phase 2a Parkinson's Trial Of JOTROL | https://www.nasdaq.com/articles/jupiter-neurosciences-starts-phase-2a-parkinsons-trial-jotrol
- N2 | 2026-08-22 | www.nasdaq.com | Jupiter Posts Wider Loss In Q2, Announces Pricing Of $2 Mln Direct Offering | https://www.nasdaq.com/articles/jupiter-posts-wider-loss-q2-announces-pricing-2-mln-direct-offering
- N3 | 2026-05-20 | www.nasdaq.com | Jupiter Neurosciences Surges On Securing $100 Mln Term Sheet For ALA-002's US Licensing Rights | https://www.nasdaq.com/articles/jupiter-neurosciences-surges-securing-100-mln-term-sheet-ala-002s-us-licensing-rights
- N4 | 2026-01-28 | www.globenewswire.com | Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users | https://www.globenewswire.com/news-release/2026/01/28/3227379/0/en/Jupiter-Neurosciences-Expands-Nugevia-Addressable-Market-with-Focus-on-GLP-1-Users.html
- N5 | 2026-01-28 | www.nasdaq.com | Jupiter Neurosciences To Showcase Lead Program JOTROL At The DealFlow Discovery Conference | https://www.nasdaq.com/articles/jupiter-neurosciences-showcase-lead-program-jotrol-dealflow-discovery-conference
- N6 | 2025-07-23 | www.nasdaq.com | Jupiter Neurosciences Highlights Breakthrough JOTROL™ Resveratrol Platform with Enhanced Bioavailability and Therapeutic Potential | https://www.nasdaq.com/articles/jupiter-neurosciences-highlights-breakthrough-jotroltm-resveratrol-platform-enhanced
- N7 | 2025-06-30 | www.nasdaq.com | Jupiter Neurosciences Launches Nugevia™ PWR: A Science-Driven Cellular Energy Supplement for Longevity | https://www.nasdaq.com/articles/jupiter-neurosciences-launches-nugeviatm-pwr-science-driven-cellular-energy-supplement
- N8 | 2025-06-23 | www.nasdaq.com | Jupiter Neurosciences Appoints Annika Sörenstam as First Brand Ambassador for Nugevia™ Longevity Supplement Line | https://www.nasdaq.com/articles/jupiter-neurosciences-appoints-annika-sorenstam-first-brand-ambassador-nugeviatm-longevity
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


